UK's Hikma Pharma holds annual outlook, preps for US generic drug tariffs

Hikma Pharmaceuticals reported a 9% rise in half-year core operating profit and reiterated its annual outlook. The beat was attributed to turnaround efforts to expand the product base and streamline manufacturing, supporting continued execution. Overall, the update is modestly positive for earnings confidence, though guidance was maintained rather than raised.

Analysis

Hikma Pharmaceuticals reported a 9% rise in half-year core operating profit and reiterated its annual outlook. The beat was attributed to turnaround efforts to expand the product base and streamline manufacturing, supporting continued execution. Overall, the update is modestly positive for earnings confidence, though guidance was maintained rather than raised.